These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 31348283)
1. Noninvasive diagnosis of hereditary transthyretin-related cardiac amyloidosis: A case report. Qin J; Zhan C; Li H; Han Y; Wang H; Li R; Ma F; Yan J Medicine (Baltimore); 2019 Jul; 98(30):e16566. PubMed ID: 31348283 [TBL] [Abstract][Full Text] [Related]
2. Non-invasive detection and differentiation of cardiac amyloidosis using Takasone K; Katoh N; Takahashi Y; Abe R; Ezawa N; Yoshinaga T; Yanagisawa S; Yazaki M; Oguchi K; Koyama J; Sekijima Y Amyloid; 2020 Dec; 27(4):266-274. PubMed ID: 32722948 [TBL] [Abstract][Full Text] [Related]
3. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report. Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273 [TBL] [Abstract][Full Text] [Related]
4. Combination of Commonly Examined Parameters Is a Useful Predictor of Positive Marume K; Takashio S; Nishi M; Hirakawa K; Yamamoto M; Hanatani S; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Sakamoto K; Yamamoto E; Kaikita K; Izumiya Y; Yamashita Y; Ando Y; Tsujita K Circ J; 2019 Jul; 83(8):1698-1708. PubMed ID: 31189791 [TBL] [Abstract][Full Text] [Related]
5. Wild type cardiac amyloidosis: is it time to order a nuclear technetium pyrophosphate SPECT imaging study? Shen CP; Vanichsarn CT; Pandey AC; Billick K; Rubenson DS; Mohan RC; Heywood JT; Srivastava AV Int J Cardiovasc Imaging; 2023 Jan; 39(1):201-208. PubMed ID: 36598681 [TBL] [Abstract][Full Text] [Related]
6. False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain: Case report. Zeng Y; Poterucha TJ; Einstein AJ; Zhang Q; Chen Y; Xie H; Wan K; Liang Y; Chen J; Tang G Medicine (Baltimore); 2021 Apr; 100(17):e25582. PubMed ID: 33907108 [TBL] [Abstract][Full Text] [Related]
7. Noninvasive risk stratification of patients with transthyretin amyloidosis. Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252 [TBL] [Abstract][Full Text] [Related]
8. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572 [TBL] [Abstract][Full Text] [Related]
9. A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy. Zhang KW; Zhang R; Deych E; Stockerl-Goldstein KE; Gorcsan J; Lenihan DJ Am Heart J; 2021 Feb; 232():137-145. PubMed ID: 33212046 [TBL] [Abstract][Full Text] [Related]
12. Validation of the Kumamoto criteria for prediction of Ochi Y; Kubo T; Baba Y; Ueda M; Miyagawa K; Noguchi T; Hirota T; Yamasaki N; Kitaoka H J Cardiol; 2021 Feb; 77(2):124-130. PubMed ID: 33132078 [TBL] [Abstract][Full Text] [Related]
13. Prompt diagnosis of a wild-type transthyretin cardiac amyloidosis: Role of multimodality imaging. Lim SS; Kuo L; Chang FP; Chang CC; Yu WC J Chin Med Assoc; 2022 Nov; 85(11):1101-1105. PubMed ID: 36194162 [TBL] [Abstract][Full Text] [Related]
14. Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population. Bourque JM; Schepart A; Bhambri R; Castaño A; O'Brien A; Chen Y; Prasad S; Roy A; Grodin JL Am J Cardiol; 2022 Mar; 167():98-103. PubMed ID: 35022130 [TBL] [Abstract][Full Text] [Related]
15. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Castaño A; Narotsky DL; Hamid N; Khalique OK; Morgenstern R; DeLuca A; Rubin J; Chiuzan C; Nazif T; Vahl T; George I; Kodali S; Leon MB; Hahn R; Bokhari S; Maurer MS Eur Heart J; 2017 Oct; 38(38):2879-2887. PubMed ID: 29019612 [TBL] [Abstract][Full Text] [Related]
16. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction. Chen W; Ton VK; Dilsizian V Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480 [TBL] [Abstract][Full Text] [Related]
17. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869 [TBL] [Abstract][Full Text] [Related]
18. Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure? Jonker DL; Hazenberg BPC; Nienhuis HLA; Slart RHJA; Glaudemans AWJM; Noordzij W J Nucl Cardiol; 2020 Oct; 27(5):1774-1784. PubMed ID: 30374850 [TBL] [Abstract][Full Text] [Related]
19. A challenging road to diagnosing transthyretin cardiac amyloidosis and using technetium-99m pyrophosphate bone scintigraphy in nuclear cardiology - A case report. Kavita A; Abdul Onny MA; Suppiah S; Abdul Aziz AF; Hashim H; Raja Shariff RE; Ng CS Med J Malaysia; 2021 Sep; 76(5):762-767. PubMed ID: 34508392 [TBL] [Abstract][Full Text] [Related]
20. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]